Premium
Functional and oncologic outcome of cemented endoprosthesis for malignant proximal femoral tumors
Author(s) -
Houdek Matthew T.,
Watts Chad D.,
Wyles Cody C.,
Rose Peter S.,
Taunton Michael J.,
Sim Franklin H.
Publication year - 2016
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24339
Subject(s) - medicine , surgery , sarcoma , femur , cohort , implant , complication , pathology
Background Cemented endoprosthetic replacement is an option for reconstruction of the proximal femur to achieve limb salvage. Existing outcome studies combine benign and malignant conditions, or group endoprostheses from multiple areas into one cohort. We sought to examine a series of endoprosthetic replacements of the proximal femur for a malignant process. Methods We reviewed 204 patients who underwent an endoprosthesis for a malignant process of the proximal femur with at least 2‐year follow‐up. Mean age was 59 years, with 55% being male. The most common pathology was metastatic disease (n = 120, 59%). Mean follow‐up was 7 years (2–22 years). Mean time to death was 2 years (range 2 weeks–18 years). A bipolar component was used in 93% of patients. Results 5‐year survival was 8% in patients with metastatic disease and 54% for patients with primary disease. Local recurrence and metastatic disease developed in 5 and 19 patients with a primary sarcoma. Following the procedure the mean Harris Hip and Musculoskeletal Tumor Society Scores were 75 and 18. Conclusion Patients typically succumb to their disease prior to implant failure; however, endoprosthetic replacement provides patients with an acceptable means of functional recovery with an acceptable complication profile. J. Surg. Oncol. 2016;114:501–506 . © 2016 Wiley Periodicals, Inc.